Search results
Tematy dnia
2 lip 2024 · Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ 3, which is focused on preventing symptomatic Alzheimer's disease in participants with preclinical AD; TRAILBLAZER-ALZ 5, a registration trial for early symptomatic AD currently enrolling in China and Korea; and TRAILBLAZER-ALZ 6, which is focused on ...
2 lip 2024 · The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope, disappointment and...
The trial was originally designed as a phase 2 trial with a plan to enroll 500 participants and assess CDR-SB as the primary outcome, but was subsequently amended to a phase 3 trial assessing the iADRS score as the primary outcome in February 2021 in an effort to confirm and expand the results of the TRAILBLAZER-ALZ trial.
11 cze 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early...
17 lip 2023 · We tested solanezumab, which targets monomeric amyloid, in a phase 3 trial involving persons with preclinical Alzheimer’s disease. Persons 65 to 85 years of age with a global Clinical Dementia ...
2 lip 2024 · The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease.
17 lip 2023 · A new drug, donanemab, is being hailed as a turning point in the fight against Alzheimer's, after a global trial confirms it slows cognitive decline.
